reason report
structur industri headwind continu pt reduc
bottom line walgreen report disappoint
result follow call remain cautiou stock
highlight ahead quarter link believ continu industri
consolid preval narrow network caus sustain
reimburs pressur op compet
volum call ceo stefano pessina point increas
reimburs pressur lower gener deflat brand inflat
lower benefit store optim program
primari headwind face busi quarter believ
reimburs competit pressur unlik abat
time soon work drug price trend suggest headwind
price also continu though expand cost reduct
program continu work modern busi sound like
compani continu make signific invest
busi partnership intend drive futur growth
howev invest may off-set cost reduct
benefit appear like retail pharmaci minim purchas
power appear partnership offset
reimburs headwind remain cautiou price
declin reduc outlook
pharmaci margin busi model remain pressur
pharmaci market challeng right accord
manag reimburs rate drug price pressur
continu impact busi call manag explain
continu gener deflat lower expect brand inflat
reduc opportun mitig reimburs pressur
result declin margin retail pharmaci usa
gross margin declin bp y/i rel
declin bp two year period unfortun
margin pressur headwind compani face
same-stor growth pharmaci front-of-stor
behind plan comp retail sale quarter
y/i though bp declin reportedli due tough cold
flu comp straight quarter neg growth
continu highlight store optim work result
yet materi becom clear tradit pharmaci
busi us remain sever persist pressur amid
look like race bottom link
net debt total capit
price-to-earnings lt ep growth
ep
year price history/av daili volume mil
compani inform svb leerink llc research
ep exclud acquisition-rel cost acquisition-rel amort non-recur item includ lifo adjust revenu billion
pleas refer page import disclosur price chart analyst certif
guidanc revis drastic expect
slash guidanc underscor magnitud pressur
face challeng second-half expect manag
continu reimburs pressur us gener weak
uk market cite two primari driver manag
expect challeng prior adj ep guid
growth slash roughli flat y/i despit lower tax rate
higher share repurchas assumpt estim alreadi
exceed origin share repurchas guidanc complet
buyback appear like guid
addit repurchas total reportedli contribut
adj ep
long-term guidanc underwhelm support cautiou
outlook expect adj ep flat y/i longer-
term expect adj ep growth mid-to-high singl digit rang
howev expect annual buyback contribut growth
adj ep impli core adj ep growth well
behind double-digit adj ep growth report past year
support outlook manag claim good line
sight lever counteract reimburs pressur worri
line sight may slightli blurri given continu gener deflat
difficult oper environ
hire senior execut may step right direct
probabl game-chang found peculiar
earn call manag highlight hire host
senior execut drive perform improv hire new
head digit oper new leadership market like
good step believ ad senior execut solv
structur issu like partnership
invest technolog
invest buy growth may off-set cost cut initi
encourag hear expand cost save
target annual save concern
plan invest may off-set signific portion
benefit cost cut initi exampl
invest store labor invest said
detract bp margin quarter next three year
guid invest op-ex
view invest next three-year like
off-set signific portion benefit realiz cost
save program manag expect invest drive
growth invest store optim digit yet
bear fruit evidenc quarterli result
remain signific pressur
retail remain signific pressur revenu y/
adj oper profit y/i despit cut fte
headcount uk headquart boot uk continu
drag segment continu revenu adj op declin
manag continu work beauti experi sourc
growth margin stabil remain concern potenti
continu reimburs pressur
model updat follow quarter updat model lower
price target account reduc guid tepid
long-term outlook adj ep declin
adj ep declin result lower price target
ep
largest global pharmaci led retail pharmaceut wholesal
organ world walgreen us drugstor chain largest pharmaci chain
us store count industri size improv purchas power brand-nam
recognit improv store traffic overal volum health plan self-insur
employ seek reduc medic cost via restrict network believ walgreen in-stor
clinic may provid attract altern plan walgreen nation presenc
also attract mani plan view provid larg corpor broad access
view gener launch wave next sever year posit impact
bottom line walgreen balanc reward custom loyalti program help lower
print ad cost bring individu market benefit recent work increas wba
privat brand product share mix well new front-end merchandis strategi
posit impact same-stor sale profit addit walgreen recent deal allianc
boot abc/op offer promis long-term synergi global
growth back lost share esrx network disput
although grow accept narrow network remain risk walgreen provid
health plan wide array servic includ infus specialti dispens lab servic
hospit partnership primari care servic case walgreen also earli
mover advantag purchas jv boot deal walgreen
pbm may advantag case make retail chain payer agnost
mani strength believ retail channel face signific challeng
includ increasingli competit environ seek creat
restrict prefer narrow network deal effort captur store traffic volum
medacorp specialist check indic retail rate reduc
case keep pressur retail gross margin
furthermor on-going gener launch believ wave
larg behind us becom increasingli difficult show gross margin expans
retail also believ transact posit busi stock howev
deterior lose share even though deal approv investor
sentiment stock name appear low lastli threat amazon entri
pharmaci servic space continu weigh stock believ
retail exposur sinc own pbm given risk
concern rate share market perform
next month expect share trade ep
would put stock price multipl reflect on-going
reimburs pressur minim accret continu headwind
intern busi believ posit win share becom
extens network vast array clinic capabl believ new manag
team take step reduc overal cost increas sale higher margin front-stor
product posit retail rate remain signific pressur brand
gener price also headwind becom aggress overal
respons market also overhang unlik abat time soon given
challeng concern rate share market perform
competit high retail pharmaci industri highli competit contract
pbm manufactur also competit walgreen compet chain
independ drug store well mail order prescript provid groceri store on-line
pharmaci pharmaceut vendor chang competit landscap
impact rx volum neg impact compani sale earn
macroeconom regulatori climat uncertainti continu econom slowdown
 would bode poorli sinc above-averag unemploy rate drive lower level
consum spend would decreas prescript drug util regulatori environ
also fair amount uncertainti time impact variou healthcar reform
provis could materi impact wba oper nation emphasi reduc healthcar
cost could also spawn reimburs pressur new way contain healthcar cost
devis implement
intern exposur execut risk walgreen merger allianc boot increas
exposur intern market increas currenc exposur regulatori risk
wba partnership uniqu approach contract distribut
compani fail execut vision accret could expect
season time cost adjust swing result front-end sale
prescript sale compon season sale also lumpi depend
holiday line calendar sever cold cough flu season
magnitud compani lifo provis also fluctuat given quarter depend
inventori level sale inflat also swing result contribut earn
miss beat
amazon entri amazon may seek disrupt pharmaci market enter
retail market buy build contract pbm news topic pose
headlin risk share amazon could formid competitor mail cash pay
incom statement model fiscal year end august mm
compani report svb leerink llc estim
compani report svb leerink llc estim
sale
revenu
revenu
gross profit sg spread bp
equiti earn ab
share allianc boot associ
sale acquisit adjust
revenu
revenu
net earn attr nci
revenu
total non-gaap adjust tax
revenu
revenu
equiti earn allianc boot
sale acquisit adjust
incom statement model fiscal year end august mm
revenu
revenu
revenu
revenu
adjust equiti earn
elimin unalloc
sale
compani report svb leerink llc estim
incom statement model fiscal year end august mm
sale
equiti earn allianc boot
share allianc boot associ
previous held equiti interest
tax earn equiti method invest
net incom attrib non-control interest
net incom attrib walgreen
gain previous held equiti interest
increas decreas fair market valu warrant
partial releas capit loss valuat allow
loss sale busi
gain previous held equiti interest
increas decreas fair market valu warrant
partial releas capit loss valuat allow
compani report svb leerink llc estim
